Cyteir Secures $80 Million Series C Financing to Advance Novel Cancer Therapy Program

Entrepreneurship
Written By

Cyteir Secures $80 Million Series C Financing to Advance Novel Cancer Therapy Program

by David E Shaw

As a co-founder of Cyteir Therapeutics, and chair emeritus of The Jackson Laboratory where this technology originated with Dr. Kevin Mills, I share news of Cyteir’s $80mm Series C financing. And I send congratulations to the Cyteir team for their remarkable accomplishments!

Read Cyteir's press release

Previous

Arctaris Welcomes David Evans Shaw to Board of Advisors
Next

Shaw Innovation Explorers Program Launches with UNH